Trial Profile
Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 19 Apr 2022 Planned primary completion date changed from 3 Apr 2021 to 3 Sep 2022.
- 21 Sep 2020 Planned primary completion date changed from 3 Jun 2020 to 3 Apr 2021.
- 28 Aug 2019 Planned primary completion date changed from 30 Apr 2019 to 3 Jun 2020.